carbon monoxide has been researched along with Hematologic Diseases in 11 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
Hematologic Diseases: Disorders of the blood and blood forming tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In multivariate analysis, chronic graft-versus-host disease (relative risk, 16) and pretransplantation diffusion capacity for carbon monoxide or forced expiratory volume in the first second <80% predicted were independently associated with a late decrease in PF from baseline (relative risk, 7)." | 3.73 | Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. ( Barrett, AJ; Childs, R; Karimpour, S; Mielke, S; Montero, A; Rezvani, K; Savani, BN; Shenoy, A; Singh, A; Srinivasan, R, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (72.73) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Le Bourgeois, A | 1 |
| Malard, F | 1 |
| Chevallier, P | 1 |
| Urbistandoy, G | 1 |
| Guillaume, T | 1 |
| Delaunay, J | 1 |
| Peterlin, P | 1 |
| Lemarchand, P | 1 |
| Germaud, P | 1 |
| Mohty, M | 1 |
| Moreau, P | 1 |
| Chambellan, A | 1 |
| Franco, RS | 1 |
| ENGSTEDT, L | 1 |
| OSKI, FA | 1 |
| ALTMAN, AA | 1 |
| WALLER, HD | 1 |
| STAHL, W | 1 |
| PALMACARLOS, AG | 1 |
| PALMACARLOS, ML | 1 |
| DUCLASOARES, A | 1 |
| Savani, BN | 1 |
| Montero, A | 1 |
| Srinivasan, R | 1 |
| Singh, A | 1 |
| Shenoy, A | 1 |
| Mielke, S | 1 |
| Rezvani, K | 1 |
| Karimpour, S | 1 |
| Childs, R | 1 |
| Barrett, AJ | 1 |
| Winchell, HS | 1 |
| Bratteby, LE | 1 |
| Karendal, B | 1 |
| Wadman, B | 1 |
| Gydell, K | 1 |
| Stupfel, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans Syndrome[NCT01287078] | Phase 2 | 25 participants (Actual) | Interventional | 2011-01-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with progressive disease at baseline with decline in FEV1 greater than 10% (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 2 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with progressive disease at baseline with stablization of FEV1 (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 2 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with stable disease at baseline with stablization in FEV1 and greater than 25% decline in systemic immunosuppression (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 3 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants who did not respond to treatment with cyclosporine inhalation solution (CIS) (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 7 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 2 |
Participants who responded to treatment with cyclosporine inhalation solution (CIS) (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 9 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with stable disease at baseline with stablization of FEV1 and no change or increase in systemic immunosuppresion (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 4 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 2 |
Participants with stable or progressive disease at baseline with greater than 20% of decline in FEV1 (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 1 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with stable or progressive disease at baseline with improvement of FEV1 (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 4 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
2 reviews available for carbon monoxide and Hematologic Diseases
| Article | Year |
|---|---|
The measurement and importance of red cell survival.
Topics: Anemia; Animals; Biotinylation; Breath Tests; Carbon Monoxide; Chromium Isotopes; Chromium Radioisot | 2009 |
Quantitation of red cell and heme production and destruction using radioisotope kinetics.
Topics: Animals; Autoradiography; Blood Volume Determination; Carbon Isotopes; Carbon Monoxide; Cell Surviva | 1968 |
1 trial available for carbon monoxide and Hematologic Diseases
| Article | Year |
|---|---|
Impact of pre-transplant diffusion lung capacity for nitric oxide (DLNO) and of DLNO/pre-transplant diffusion lung capacity for carbon monoxide (DLNO/DLCO) ratio on pulmonary outcomes in adults receiving allogeneic stem cell transplantation for hematologi
Topics: Adult; Aged; Allografts; Carbon Monoxide; Female; Hematologic Diseases; Hematopoietic Stem Cell Tran | 2016 |
8 other studies available for carbon monoxide and Hematologic Diseases
| Article | Year |
|---|---|
Endogenous formation of carbon monoxide in hemolytic disease; with special regard to quantitative comparisons to other hemolytic indices.
Topics: Carbon Monoxide; Cell Death; Hematologic Diseases; Hemoglobins; Hemolysis; Humans | 1957 |
Carboxyhemoglobin levels in hemolytic disease of the newborn.
Topics: Carbon Monoxide; Carboxyhemoglobin; Erythroblastosis, Fetal; Fetus; Hematologic Diseases; Hemoglobin | 1962 |
[THE VALUE OF TOTAL HEMOGLOBIN (HBT) DETERMINATION FOR THE EVALUATION OF THE COURSE OF HEMATOLOGIC DISEASES].
Topics: Anemia; Anemia, Hypochromic; Anemia, Pernicious; Carbon Monoxide; Hematologic Diseases; Hemoglobinom | 1963 |
[THE STUDY OF SERUM CO CONCENTRATION IN SOME HEMOPATHIES].
Topics: Anemia; Blood; Carbon Monoxide; Hematologic Diseases; Hemoglobinuria; Hemoglobinuria, Paroxysmal; Hu | 1964 |
Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation.
Topics: Adolescent; Adult; Carbon Monoxide; Child; Chronic Disease; Comorbidity; Disease Progression; Female | 2006 |
[Determination of THb with CO- respectively 51 Cr-technic].
Topics: Carbon Monoxide; Chromium Isotopes; Erythrocytes; Hematologic Diseases; Hemoglobins; Humans | 1971 |
Simplified method for determining carbon monoxide hemoglobin saturation in diagnosis of hemolytic disorders.
Topics: Carbon Monoxide; Hematologic Diseases; Hemoglobins; Hemolysis; Humans; In Vitro Techniques; Oxygen; | 1966 |
[The physiological stores of carbon monoxide in the body].
Topics: Air Pollution; Body Composition; Carbon Monoxide; Hematologic Diseases; Hemoglobins; Humans; Methods | 1970 |